Electra Therapeutics Inc.
ETRAHealthcare|Medical - Pharmaceuticals|US
$7.80
+0.45 (+6.12%)
Ownership Breakdown
21.2M
Shares Outstanding
Major Holders (8)
Combined: 52.3%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | Investment adviser | 11.00% | 6,885,170 | Sep 25, 2026 | 13D/G |
| Dr. Beth C. Seidenberg | Individual | 10.10% | 6,347,539 | Oct 29, 2026 | 13D/G |
| Orbimed Capital GP VII LLC | Other | 8.20% | 5,126,891 | Sep 25, 2026 | 13D/G |
| Westlake BioPartners Fund I, L.P. | Partnership | 5.60% | 3,527,136 | Oct 29, 2026 | 13D/G |
| Westlake BioPartners GP I, LLC | Other | 5.60% | 3,527,136 | Oct 29, 2026 | 13D/G |
| Westlake BioPartners Fund II, L.P. | Partnership | 4.50% | 2,820,403 | Oct 29, 2026 | 13D/G |
| Westlake BioPartners GP II, LLC | Other | 4.50% | 2,820,403 | Oct 29, 2026 | 13D/G |
| OrbiMed Genesis GP LLC | Other | 2.80% | 1,758,279 | Sep 25, 2026 | 13D/G |
Insider Trades (98)
Last 4 quarters: 15,575,761 acquired · 8,557,325 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | director, 10 percent owner: | Nov 5, 2026 | BUY | 30,891 | $7.31 | $225.8K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 4, 2026 | BUY | 5,000 | $7.07 | $35.4K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 4, 2026 | BUY | 9,267 | $7.78 | $72.1K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 3, 2026 | BUY | 24,400 | $7.88 | $192.3K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 3, 2026 | BUY | 24,313 | $7.84 | $190.6K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 5, 2026 | BUY | 125,200 | $7.31 | $915.2K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 4, 2026 | BUY | 20,000 | $7.07 | $141.4K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 4, 2026 | BUY | 37,100 | $7.78 | $288.6K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 3, 2026 | BUY | 98,600 | $7.88 | $777.0K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Nov 3, 2026 | BUY | 97,800 | $7.84 | $766.8K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 5, 2026 | BUY | 30,891 | $7.31 | $225.8K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 4, 2026 | BUY | 5,000 | $7.07 | $35.4K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 4, 2026 | BUY | 9,267 | $7.78 | $72.1K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 3, 2026 | BUY | 24,400 | $7.88 | $192.3K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 3, 2026 | BUY | 24,313 | $7.84 | $190.6K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 5, 2026 | BUY | 125,200 | $7.31 | $915.2K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 4, 2026 | BUY | 20,000 | $7.07 | $141.4K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 4, 2026 | BUY | 37,100 | $7.78 | $288.6K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 3, 2026 | BUY | 98,600 | $7.88 | $777.0K | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Nov 3, 2026 | BUY | 97,800 | $7.84 | $766.8K | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | BUY | 333,333 | $15.00 | $5.0M | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 1,703,314 | — | — | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 1,087,934 | — | — | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 2,002,310 | — | — | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | BUY | 1,000,000 | $15.00 | $15.0M | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 758,279 | — | — | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 1,087,934 | — | — | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 2,002,310 | — | — | Form 4 |
| GORDON CARL L | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 758,279 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | BUY | 333,333 | $15.00 | $5.0M | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 1,703,314 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 1,087,934 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 2,002,310 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | BUY | 1,000,000 | $15.00 | $15.0M | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 758,279 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 2,002,310 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 1,087,934 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Sep 21, 2026 | CONVERSION | 758,279 | — | — | Form 4 |
| Westlake BioPartners Fund I, L.P. | 10 percent owner | Sep 21, 2026 | OTHER | 0 | — | — | Form 4 |
| Westlake BioPartners Fund I, L.P. | 10 percent owner | Sep 21, 2026 | OTHER | 0 | — | — | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 21, 2026 | CONVERSION | 63,656 | — | — | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 21, 2026 | CONVERSION | 63,656 | — | — | Form 4 |
| Stagliano Nancy | director | Sep 21, 2026 | CONVERSION | 255,635 | — | — | Form 4 |
| Stagliano Nancy | director | Sep 21, 2026 | CONVERSION | 255,635 | — | — | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 21, 2026 | CONVERSION | 85,504 | — | — | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 21, 2026 | CONVERSION | 85,504 | — | — | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 21, 2026 | CONVERSION | 455,484 | — | — | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 21, 2026 | CONVERSION | 455,484 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director | Sep 18, 2026 | OTHER | 2,002,310 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director | Sep 18, 2026 | OTHER | 1,087,934 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director | Sep 18, 2026 | OTHER | 758,279 | — | — | Form 4 |
| ORBIMED ADVISORS LLC | director | Sep 18, 2026 | OTHER | 1,703,314 | — | — | Form 4 |
| Tucker David J. | Principal Accounting Officer | Sep 18, 2026 | OTHER | 114,000 | $4.96 | $565.4K | Form 4 |
| Tucker David J. | Principal Accounting Officer | Sep 18, 2026 | OTHER | 73,402 | $15.00 | $1.1M | Form 4 |
| Fust Matthew K | director | Sep 18, 2026 | OTHER | 59,086 | $4.40 | $260.0K | Form 4 |
| Fust Matthew K | director | Sep 18, 2026 | OTHER | 77,714 | $4.96 | $385.5K | Form 4 |
| Fust Matthew K | director | Sep 18, 2026 | OTHER | 22,632 | $15.00 | $339.5K | Form 4 |
| Dao Kim-Hien | Chief Medical Officer | Sep 18, 2026 | OTHER | 62,631 | $4.40 | $275.6K | Form 4 |
| Dao Kim-Hien | Chief Medical Officer | Sep 18, 2026 | OTHER | 23,634 | $4.40 | $104.0K | Form 4 |
| Dao Kim-Hien | Chief Medical Officer | Sep 18, 2026 | OTHER | 103,992 | $5.05 | $525.2K | Form 4 |
| Dao Kim-Hien | Chief Medical Officer | Sep 18, 2026 | OTHER | 47,269 | $5.05 | $238.7K | Form 4 |
| Dao Kim-Hien | Chief Medical Officer | Sep 18, 2026 | OTHER | 309,676 | $4.96 | $1.5M | Form 4 |
| Dao Kim-Hien | Chief Medical Officer | Sep 18, 2026 | OTHER | 155,979 | $15.00 | $2.3M | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 18, 2026 | OTHER | 101,147 | $4.40 | $445.0K | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 18, 2026 | OTHER | 219,562 | $4.96 | $1.1M | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 18, 2026 | OTHER | 155,979 | $15.00 | $2.3M | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 18, 2026 | OTHER | 46,122 | $15.00 | $691.8K | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 18, 2026 | OTHER | 4,193 | $15.00 | $62.9K | Form 4 |
| Parry Graham | Chief Scientific Officer | Sep 18, 2026 | OTHER | 85,504 | — | — | Form 4 |
| Parry Graham | Principal Accounting Officer | Sep 18, 2026 | OTHER | 114,000 | $4.96 | $565.4K | Form 4 |
| Parry Graham | Principal Accounting Officer | Sep 18, 2026 | OTHER | 73,402 | $15.00 | $1.1M | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 35,451 | $5.23 | $185.4K | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 47,269 | $4.40 | $208.0K | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 18,907 | $5.05 | $95.5K | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 47,269 | $4.96 | $234.5K | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 231,941 | $4.96 | $1.2M | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 155,979 | $15.00 | $2.3M | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 11,800 | $15.00 | $177.0K | Form 4 |
| Koe Gary S. | Chief Technical Officer | Sep 18, 2026 | OTHER | 63,656 | — | — | Form 4 |
| GORDON CARL L | director | Sep 18, 2026 | OTHER | 2,002,310 | — | — | Form 4 |
| GORDON CARL L | director | Sep 18, 2026 | OTHER | 1,087,934 | — | — | Form 4 |
| GORDON CARL L | director | Sep 18, 2026 | OTHER | 758,279 | — | — | Form 4 |
| GORDON CARL L | director | Sep 18, 2026 | OTHER | 1,703,314 | — | — | Form 4 |
| GORDON CARL L | director | Sep 18, 2026 | OTHER | 22,632 | $15.00 | $339.5K | Form 4 |
| Clark Christopher William | Chief Financial Officer | Sep 18, 2026 | OTHER | 319,202 | $4.96 | $1.6M | Form 4 |
| Clark Christopher William | Chief Financial Officer | Sep 18, 2026 | OTHER | 292,781 | $15.00 | $4.4M | Form 4 |
| Stagliano Nancy | director | Sep 18, 2026 | OTHER | 94,538 | $5.23 | $494.4K | Form 4 |
| Stagliano Nancy | director | Sep 18, 2026 | OTHER | 288,814 | $4.96 | $1.4M | Form 4 |
| Stagliano Nancy | director | Sep 18, 2026 | OTHER | 68,819 | $15.00 | $1.0M | Form 4 |
| Stagliano Nancy | director | Sep 18, 2026 | OTHER | 255,635 | — | — | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 59,086 | $5.23 | $309.0K | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 281,987 | $4.40 | $1.2M | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 70,903 | $4.96 | $351.7K | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 759,198 | $4.96 | $3.8M | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 927,155 | $15.00 | $13.9M | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 167,798 | $15.00 | $2.5M | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 32,092 | $15.00 | $481.4K | Form 4 |
| Dong Quehuong (Kathy) | director, officer: President & CEO | Sep 18, 2026 | OTHER | 455,484 | — | — | Form 4 |